BlinkLab

The Pharmacology of Human Decision Making Study with Monash University

BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”), an innovative digital healthcare company developing smartphone-based AI powered diagnostic tests for neurological disorders, is pleased to announce a new study to run in partnership with Monash University. The study will evaluate BlinkLab as a medical device able to monitor the therapeutic effects of ketamine on cognitive processes whereby sensory information is converted into decision making. In the future, results from this study can help facilitate cognitive behavioural therapy outcomes in patients with psychiatric conditions such as depression, schizophrenia, epilepsy, and post-traumatic stress disorder (PTSD).


Highlights

  • Study provides a unique opportunity to discover the building blocks of cognition with the potential to transform our understanding of a range of clinical conditions including depression, schizophrenia, epilepsy, PTSD.
  • Potential to demonstrate that drugs targeting glutamatergic neurotransmission can treat some aspects of psychiatric disease symptomology or improve the efficacy of cognitive behavioural therapy.
  • Evaluates ability of BlinkLab tests to be used as a tool to measure pharmacological effects of existing and novel therapeutic agents.

Significance of the Study

Perceptual decision-making is a fundamental cognitive process where sensory information is transformed into meaningful interpretations of the environment, guiding our actions. This field has flourished through the integration of neuroscience and mathematical modelling , providing a robust framework for investigating the neural mechanisms involved. The core idea is that decisions are based on the accumulation of sensory evidence until a decision threshold is reached. These advancements offer a unique opportunity to uncover the fundamental components of cognition and have the potential to revolutionise our understanding of various clinical conditions. By characterising underlying mechanistic abnormalities, refining clinical classifications, and identifying intervention targets, this research holds promise for significant clinical advancements and new therapies for a variety of psychiatric and neurodevelopmental conditions.

The study, conducted by the School of Psychological Sciences at Monash University will investigate the impact of glutamate challenge on perceptual decision making (including behavioural performance, sensorimotor gating) by administering ketamine while participants perform a prepulse inhibition test using BlinkLab application.

The study will be able to demonstrate whether administration of ketamine can disrupt basic sensory encoding mechanisms, which will be detectable in reduced prepulse inhibition.

Study Design

The study will recruit up to 35 healthy adults between 18-55 years old. Each participant will complete 3 testing sessions after ketamine administration. Their participation is expected to take 4-5 weeks per subject.

Terms of the Collaboration Agreement (“Agreement”)

  • Responsibilities: BlinkLab will provide access to its technology, data and shall facilitate the use of its platform during the term of the Agreement.
  • Financial arrangements: None at the date of signing (to be determined via mutual agreement in the future and in a separate agreement).
  • Intellectual Property: Each party will retain all right, title and interest in and to its background intellectual property (copyright, trademarks, designs, know how, patents, plant varieties, confidential information and all other intellectual property as defined in article 2 of the Convention establishing the World Intellectual Property Organization 1967). Any project IP (generated through the study) will be owned by Monash University.
  • Term: Date of signature by the last party to sign (5 August 2024), until completion of the Research Project as communicated by Monash.
  • Termination: Either party may terminate this Agreement by giving between 5 and 20 days written notice (at the terminating party’s election) to the other party if the other party commits a material breach of the Agreement and does not remedy that breach within 10 days after receiving notice requiring them to do so. Monash may terminate this agreement with immediate effect by giving written notice to BlinkLab.
  • Confidentiality: Standard confidentiality terms for an agreement of this nature included.

This announcement has been approved by the Board of Directors.


Click here for the full ASX Release

This article includes content from Blinklab Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

BB1:AU
The Conversation (0)
BlinkLab Limited

BlinkLab Limited


Keep reading...Show less

Revolutionising Mental Health Care Through Mobile Solutions

Syntheia (CSE:SYAI)

Syntheia Announces Closing of Private Placement

Syntheia Corp. (CSE: SYAI) (syntheia.ai) (the "Company"), is pleased to announce that further to its press releases dated July 23, 2025, and September 2, 2025 the Company has closed the second tranche of its non-brokered private placement financing for gross proceeds of $709,677.48 through the issuance of 5,913,979 units (each, a "Unit") at a price of $0.12 per Unit (the "Offering").

Each Unit was comprised of one common share in the capital of the Company (each, a "Common Share") and one Common Share purchase warrant (each, a "Warrant"). Each Warrant is exercisable to acquire one Common Share at a price of $0.16 until September 2, 2030 (the "Expiry Date"), subject to an accelerated expiry in the event the volume weighted average trading price of the Common Shares exceeds $0.20 for 20 consecutive trading days, the Company may, within 10 business days of the occurrence of such event, deliver a notice to the holders of the Warrants accelerating their Expiry Date to a date that is not less than 30 days following the date of such notice and the issuance of a press release by the Company announcing the acceleration notice (the "Accelerated Exercise Period"). Any unexercised Warrants shall automatically expire at the end of the Accelerated Exercise Period.

Keep reading...Show less
Circuit board forming a brain shape on a digital blue background.

Nebius Shares Soar on US$17.4 Billion Microsoft AI Deal

Nebius Group (NASDAQ:NBIS) surged on Tuesday (September 9) after announcing a multibillion-dollar deal with Microsoft (NASDAQ:MSFT) to provide dedicated artificial intelligence (AI) infrastructure.

Valued at US$17.4 billion over five years and expandable to US$19.4 billion if demand increases, the arrangement will see Nebius supply Microsoft with computing capacity from a new data center under construction in Vineland, New Jersey.

The news sent Nebius shares up 43.3 percent to US$91.75, their highest level on record.

Keep reading...Show less
OpenAI logo on a dark screen with a soft blue gradient background.

OpenAI Taps Broadcom to Build Custom AI Chips in Face of GPU Supply Concerns

OpenAI, the company behind ChatGPT, is reportedly set to begin large-scale production of its own artificial intelligence (AI) chips through a partnership with Broadcom (NASDAQ:AVGO).

Experts in the space see the move as a bid to cut reliance on chip giant NVIDIA (NASDAQ:NVDA) and ease the global shortage of processors driving platforms like ChatGPT.

The news came after Broadcom CEO Hock Tan told analysts in a September 4 call that the company had secured a fourth major customer that has committed to a US$10 billion order.

Keep reading...Show less
Person using laptop with generative AI, ChatGPT and other symbols floating between them.

10 Generative AI Stocks to Watch as ChatGPT Soars

The launch of OpenAI’s ChatGPT created a major buzz around artificial intelligence (AI) stocks.

ChatGPT is an AI chatbot software application that uses machine-learning techniques to emulate human-written conversations. This technology is called generative AI, and it's been making an impact on myriad industries, including marketing, security, healthcare, gaming, communication, customer service and software development.

The potential behind generative AI has been the primary driver behind a major stock rally that has helped the S&P 500 (INDEXSP:.INX) and Nasdaq Composite (INDEXNASDAQ:.IXIC) reach multiple new highs since 2023.

Keep reading...Show less
RemSense CEO and Managing Director Warren Cook

RemSense Eyes More Strategic Partnerships for Global Growth

RemSense (ASX:REM) is looking to secure more strategic partnerships as the company eyes global expansion, according to CEO and Managing Director Warren Cook.

“We have a strong pipeline of services to deliver to our existing clients that's going to take us right up through to the end of the year and into the early new year. For our global growth, we see partnerships as a critical part of our strategy to give us scale and capacity to grow throughout other parts of the region,” Cook said in an interview with the Investing News Network.

RemSense’s 3D visualisation technology — called virtualplant — is used by some major companies, including Woodside Energy Group (ASX:WDS,NYSE:WDS) and Chevron (NYSE:CVX).

Keep reading...Show less
Glowing red maple leaf on digital circuit board background.

Canada's Stealthy AI Strategy: Why the Future is B2B, Not Just Chatbots

As global giants chase consumer-facing artificial intelligence (AI), Canada has adopted a different approach.

The northern nation has excelled in developing B2B AI solutions for enterprises, governments and research institutions. This discreet strategy aims to cultivate a trusted AI environment, fostering innovation and economic growth within Canada, while building a resilient ecosystem safeguarded from external influences.

While the spotlight often falls elsewhere, Canada’s AI strategy could present a unique opportunity for investors seeking long-term growth in the evolving AI landscape.

Keep reading...Show less

Latest Press Releases

Related News

×